CrushSCI.com
80Average days
69.5Median days
8Fastest days
215Longest days
1682025 publications

Paper Review Records

All Paper Review Records

30 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

26 days

Pediatric Pharmacodynamic Differences Challenge Exposure‐Matched Intranasal Epinephrine Dosing

Authors
Ercan Yılmaz; Nezihe Koker Ozer; Erdem TopalShow moreShow less
Affiliations
1. Pediatric Allergy and Immunology Department Faculty of Medicine Inonu University Malatya TurkeyShow moreShow less
Source PDF DOI Publisher page
31 days

Pain Severity Trajectories and Patient Profiles in Chronic Pain Patients Treated with Cannabis‐Based Medicinal Products: A k‐Means Clustering Analysis of the UK Medical Cannabis Registry

Authors
Simon Erridge; Aritra Datta; Aditya Mukherjee; Dhruv Vasooja; Ross Coomber; Sushil Beri; Shaheen A. Khan; Mark W. Weatherall; Michael W. Platt; James J. Rucker; Pedro A. M. Mediano; Mikael H. SodergrenShow moreShow less
Affiliations
1. Medical Cannabis Research Group Department of Surgery and Cancer Imperial College London London UK; 2. Curaleaf Clinic Curaleaf International London UK; 3. St. George's Hospital London UK; 4. Imperial College Healthcare NHS Trust London UK; 5. Guy's and St. Thomas' NHS Foundation Trust London UK; 6. Buckinghamshire Healthcare NHS Trust Amersham UK; 7. Department of Psychological Medicine King's College London London UK; 8. South London and Maudsley NHS Foundation Trust London UK; 9. Department of Computing Imperial College London London UKShow moreShow less
Source PDF DOI Publisher page
64 days

Fostering Clinical Pharmacology and Drug Development in India: A Perspective From SAC‐ACCP

Authors
Karthik Venkatakrishnan; Abhigyan Ravula; Sagar Bachhav; Mohammad Faruq; Bratati Kahali; AVS Suresh; Sanish Davis; Manish Lavhale; Amruta Gadade; Gurusharan Dumra; Vikas Dighe; Vipin Dhote; Bikash Medhi; Kiran Marthak; Nirmala Rege; Tushar Garimella; Taruna Madan; Jagannath Kota; Ravi Shankar P. Singh; Gangadhar Sunkara; Manoj Jadhav; Nilima Kshirsagar; Deven ParmarShow moreShow less
Affiliations
1. Clinical Pharmacology & Quantitative Pharmacology Clinical Pharmacology & Safety Sciences R&D, AstraZeneca Waltham MA USA; 2. Quantitative Pharmacology and Pharmacometrics Merck & Co., Inc. Rahway NJ USA; 3. CSIR‐Institute of Genomics and Integrative Biology Delhi India; 4. Centre for Brain Research Indian Institute of Science Bengaluru India; 5. AOI Hospital Hyderabad India; 6. Clinical Sciences Oncology Takeda Biopharmaceuticals India Pvt. Ltd. Mumbai India; 7. Pharmazz India Private Limited Greater Noida India; 8. National Centre for Preclinical Reproductive and Genetic Toxicology ICMR‐National Institute for Research in Reproductive and Child Health Jehangir Merwanji Street Mumbai India; 9. Department of Pharmacology Narendra Modi Medical College Ahmedabad India; 10. VNS Group of Institutions Faculty of Pharmacy Bhopal India; 11. Department of Pharmacology Postgraduate Institute of Medical Education and Research (PGIMER) Chandigarh India; 12. Veeda Lifesciences Ahmedabad India; 13. Department of Pharmacology Era's Lucknow University, Lucknow India; 14. Daiichi Sankyo Inc. Baskin Ridge NJ USA; 15. Development Research, Indian Council of Medical Research, V. Ramalingaswami Bhawan New Delhi India; 16. Novartis Healthcare Private Limited Salarpuria Sattva Knowledge City Hyderabad India; 17. Clinical Pharmacology Group Lead Pfizer Inc. Cambridge MA USA; 18. Novartis Pharmaceuticals East Hanover NJ USA; 19. ISHA Therapeutics Hillsborough NJ USA; 20. National Academy of Medical Sciences, New Delhi Maharashtra University of Health Sciences,Nashik,422004 India; 21. Clinical RnD Zydus Therapeutics Inc. 73C Route 31N Pennington NJ USAShow moreShow less
Source PDF DOI Publisher page
169 days

Development and Evaluation of a Population Pharmacokinetic Model for High‐Dose Methotrexate in Japanese Pediatric Patients with Acute Lymphoblastic Leukemia

Authors
Takuya Suzuoka; Tsubura Noda; Kota Tsuge; Yasuyoshi Ishiwata; Toshinori Hirai; Takeshi Isoda; Masatoshi Takagi; Masashi NagataShow moreShow less
Affiliations
1. Department of Pharmacy Institute of Science Tokyo Hospital Tokyo Japan; 2. Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences Institute of Science Tokyo Tokyo JapanShow moreShow less
Source PDF DOI Publisher page
65 days

Population Pharmacokinetics and Exposure–Response of Sasanlimab, a Checkpoint Inhibitor, in Patients with Non‐Muscle Invasive Bladder Cancer and Other Solid Tumors

Authors
Joanna C. Masters; Brian Jermain; Alan Liu; Rossano Cesari; Anna Maria Calella; Elisabete Michelon; Caimiao Wei; Susana Liu; Joseph PiscitelliShow moreShow less
Affiliations
1. Pfizer Inc. San Diego CA USA; 2. Pfizer Inc. New York NY USA; 3. Pfizer SRL Milan Italy; 4. Pfizer SRL Rome Italy; 5. Pfizer Inc. Quebec CanadaShow moreShow less
Source PDF DOI Publisher page
97 days

The Rise of the Digital Health Technology–AI Coupled System in the AI Era of Drug Development

Authors
Hanrui Zhang; Gabriel K. Innes; Jonas Santiago; Ayoub Suliman; Norah Xiao; Hao Zhu; Dianne Paraoan; Jeffery Siegel; Yutao Gong; Ruihao Huang; Menglun Wang; Lixia Zhang; Qi LiuShow moreShow less
Affiliations
1. Office of Clinical Pharmacology Office of Translational Sciences, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA; 2. Office of Medical Policy, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USA; 3. Office of Drug Evaluation Sciences Office of New Drugs, Center for Drug Evaluation and Research US Food and Drug Administration Silver Spring MD USAShow moreShow less
Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

We will reply within 30 minutes.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review59.6 days

Median65 days

Contact CrushSCI

Contact CrushSCI

Leave your email address to discuss academic polishing, structural refinement, or one-to-one guidance.

We will reply within 30 minutes.

Selected service: Academic Consulting Service

Leave your email address

Or email us directly at leader@crushsci.com

Enter your email address so we can reply. Your details will remain private.